et al. 5 first described CD8+CD28-T cells as a subset of suppressor cells within the CD8+ T-cell population. Growing evidence suggests that CD8+CD28-T cells are a unique subpopulation of regulatory T cells (Tregs) that exert broad effects on directly regulating T cells, such as by inhibiting their activation and proliferation, decreasing the secretion of proinflammatory cytokines by activated T cells, and inducing apoptosis in activated T cells in vitro. 6, 7 Cell contact and soluble factors, including TGF-β, IL-7, IL-10, PDL-1 and FasL, contribute to the ability of CD8+CD28-T cells to regulate T-cell responses. 6, 7 Moreover, CD8 +CD28-T cells may indirectly control T-cell responses, such as by upregulating LILRB4 and LILRB2 on antigen-presenting cells (APCs), which gives rise to tolerogenic APCs that have an impaired capacity for co-stimulating T-cell activation. 3, 8 Tolerized APCs also interact with naive CD8+ T cells, induce their expression of Foxp3 and promote their development into CD8+CD28-Foxp3+ T cells, 8 which comprise the major subset of CD8+CD28-Tregs.
Accumulating evidence indicates that CD8+CD28-T cells are associated with numerous inflammation-related disorders, regardless of age. For example, increased numbers of CD8+CD28-T cells are found in tumor microenvironments and the circulation of cancer patients, and this elevation is associated with malignancy. 3 Increases of CD8 +CD28-T cells are also observed in chronic viral infections, such as hepatitis C virus (HCV), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV) or human immunodeficiency virus (HIV) infections. 3, 9 CD8+CD28-T cells also expand after bone morrow or solid organ transplantation and may serve as a mechanism of primary tolerance in transplantation, yielding better graft acceptance and stabilizing graft function, and their expansion is associated with a reduced occurrence of rejection. 3, 10 In autoimmune diseases, such as type 1 diabetes mellitus and multiple sclerosis, 3 the CD8+CD28-T-cell population is significantly smaller than that seen in healthy controls. Subsequently, several studies have even suggested that CD8 +CD28-T cells may act as mediators in inflammation-related disease. CD8(-/-) CD28(-/-)-deficient mice are susceptible to experimental autoimmune encephalomyelitis (EAE) or fully rejected allogeneic skin allografts, and the adaptive transfer of CD8+CD28-T cells has been shown to significantly suppress EAE, alleviate acute allograft rejection, ameliorate allergic diarrhea or prevent experimental inflammatory bowel disease (IBD). 3, 10, 11 Currently, CD8+CD28-T cells contribute to the prediction of prognosis in inflammatory disease; for example, the frequency of a CD8+CD28-T-cell subset in the circulation may serve as new marker of response to antiretroviral therapy in HIV, and the CD8+CD28 +/CD8+CD28-T-cell ratio can sensitively predict the outcome for IBD patients. 9, 12 These results support the idea that CD8+CD28-T cells may Mesenchymal stem cells (MSCs) are multipotent progenitor cells that can be derived from various tissues, and they possess immunomodulatory capability for inhibiting the proliferation and cytotoxicity of T cells and NK cells, downregulating the maturation and function of dendritic cells, and controlling the proliferation and differentiation of B cells. 13 Beginning from previous reports that showed that MSCs induce traditional CD4+CD25+Foxp3+ Tregs, 13 our group demonstrated that a co-culture with MSCs increased the percentage of CD8+CD28-T cells. 6 However, there were differences in the MSC co-cultureinduced enhancements of these two Tregs. Previous work showed that MSCs significantly promoted the generation and expansion of CD4+CD25+Foxp3+ Tregs through TGF-β or PGE2. 13 However, we were unable to generate CD8 +CD28-T cells from CD8+CD28+ T cells or promote the proliferation of CD8+CD28-T cells; instead, the MSC co-culture increased the percentage of CD8+CD28-T cells in vitro by reducing apoptosis partially via IL-6 6 (Figure 1 ). Because CD8+CD28-T cells are weaker in proliferation and more prone to apoptosis compared with CD8+CD28+ T cells, 3, 6 we speculate that, in vivo, MSCs might indirectly induce the generation of CD8+CD28-T cells from naive CD8+ T cells. This hypothesis is supported by previous findings that showed MSCs induce tolerogenic APCs, 13 which can trigger the generation of CD8+CD28-Tregs from naive CD8+ T cells 8 (Figure 1 ). Future studies are warranted to test this possibility.
Importantly, it has been shown that MSCs comprehensively enhance the suppressive activity of CD8+CD28-T cells by inhibiting naive CD4+ T-cell proliferation and activation, decreasing the production of IFN-γ by activated CD4+ T cells and inducing apoptosis in activated CD4+T cells 6 (Figure 1) . The enhanced regulatory function of cocultured CD8+CD28-T cells requires an MSC-induced increase in their expression of IL-10 and FasL. 6 Although MSCs have been shown to trigger the generation and expansion of CD4+CD25 +Foxp3+ Tregs, it is not yet clear whether MSCs impact the regulatory ability of these Tregs. 13 Our studies have shown that MSCs maintain the pleiotropic effects of CD8+CD28-Tregs and can upgrade these cells to a 'next generation' of CD8+CD28-Tregs with a robust immunoregulatory function. 6, 14 These results suggest that Tregs might hold promise for future efforts aimed at treating inflammation-related diseases. However, the functional consequences of the MSC-mediated effects on CD8 +CD28-T cells should be explored further.
Given the obvious MSC-mediated changes in CD8+CD28-T cells, we speculate that induced CD8+CD28-T cells might also contribute to the well-known capacity of adopted MSCs to improve inflammation-related diseases. In clinical studies of patients with chronic graft-versus-host disease (cGVHD), which is the predominant complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), a prospective observation supports our hypothesis: CD8+CD28-T cells are elevated in patients who exhibit clinical remission of cGVHD after MSC administration, but not in those who fail to respond to MSC CD8+CD28-regulatory T cells X Chen et al therapy. 6, 14, 15 Moreover, the clinical improvement in the former group of patients was accompanied by increased expression of IL-10 and FasL on CD8 +CD28-T cells, 6 suggesting that MSCs might enhance immunosuppression of CD8+CD28-regulatory T cells to ameliorate cGVHD and other inflammationrelated diseases. Additional studies are also needed to improve our understanding of the MSC-induced enhancement of CD8+CD28-Treg activity and its ability to modulate inflammationrelated diseases.
It is tempting to believe that CD8 +CD28-Tregs could be exploited as a cell therapy for inflammatory disease. A main hurdle might be the need to expand CD8+CD28-Tregs in vitro while maintaining their functionality. It could be helpful to use MSCs and dendritic cells as supporting cells. Further efforts are needed to shape CD8+CD28-T cells as robust and pleiotropic regulatory T cells.
